

WHO approves Q-TIB drug by Cipla

30 November 2017 | News

It is for the first time that such a combination has been made available in the world.



Cipla has received an approval from the World Health Organisation (WHO) for Q-TIB, a combination drug indicated to help prevent tuberculosis infection in people living with HIV. The company will be marketing the product globally.

As per WHO's Global TB Report, 2016, about one million people died of AIDS-related illness. Most of them succumbed to infections, and among them, 4 lakh died of tuberculosis.

Q-TIB is a novel fixed dose combination in a single tablet and it is for the first time that such a combination has been made available in the world.

Q-TIB will help prevent tuberculosis infection in people living with HIV as they face a challenged immune system and are prone to infections, which constitute the major source of premature deaths among them.